A recent study has raised concerns about potential mental health risks tied to a group of medications known as Glucagon-like Peptide-1 (GLP-1) receptor agonists, which are commonly used to treat type 2 diabetes
These drugs help regulate blood sugar by mimicking a natural hormone that influences insulin production and appetite. They slow digestion, support the release of insulin as needed, and help people feel fuller for longer—making them effective for both blood sugar control and weight management.
Drugs such as OzemQpic and Mounjaro have gained popularity as weight loss drugs. While these drugs have shown weight-loss effects, the study suggests that they could affect certain genes linked to depression.
Also Read | Pfizer ends work on weight-loss pill Danuglipron
Using advanced pharmacogenomic computational methods, an international team of 24 researchers identified genetic pathways that may predispose certain individuals to depressive symptoms when using GLP-1 agonists.
The findings indicate that GLP-1 receptor agonists may disrupt dopamine balance in certain individuals, particularly those with already existing problems in dopamine systems. This disruption may increase the risk of depression, anxiety, and suicidal ideation.
Also Read | Report says fatty liver, obesity on rise in India
“This study should not be ignored, despite the hype surrounding the positive clinical outcomes of GLP1 receptor agonists,” said senior author Dr. Kenneth Blum, Research Professor at Western University Health Sciences and Ariel University. “We urge the clinical prescribing community to proceed with caution to avoid another tragic wave of ‘people dying to lose weight.’”
